- Trials with a EudraCT protocol (111)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
111 result(s) found for: Protein sequencing.
Displaying page 1 of 6.
EudraCT Number: 2019-002225-30 | Sponsor Protocol Number: 69HCL18_0957 | Start Date*: 2019-07-18 | ||||||||||||||||
Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
Full Title: Impact of low protein diet supplemented with ketoanalogues on uremic toxins production and glucose metabolism in chronic kidney disease_KETO GUT study | ||||||||||||||||||
Medical condition: chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001767-67 | Sponsor Protocol Number: PTC124-GD-045-DMD | Start Date*: 2020-01-30 |
Sponsor Name:PTC Therapeutics, Inc. | ||
Full Title: Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment with Ataluren | ||
Medical condition: Non-Sense Mutation Duchenne Muscular Dystrophy (nmDMD) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-004355-33 | Sponsor Protocol Number: MH002-UC-201 | Start Date*: 2021-09-23 | |||||||||||
Sponsor Name:MRM Health NV | |||||||||||||
Full Title: Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Mechanistic Effects, and Effects on Disease Activity of MH002 in Subjects with Mild to Moderate Ulcerative Colitis: A First-in... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004370-96 | Sponsor Protocol Number: LG-TCS-AD | Start Date*: 2019-02-15 | |||||||||||
Sponsor Name:Jacob Pontoppidan Thyssen | |||||||||||||
Full Title: The effects of topical corticosteroid use on insulin sensitivity and bone turnover | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003530-13 | Sponsor Protocol Number: 18072011 | Start Date*: 2011-12-20 | |||||||||||
Sponsor Name:Brighton & Sussex University Hospitals NHS Trust | |||||||||||||
Full Title: Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer | |||||||||||||
Medical condition: Primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003768-31 | Sponsor Protocol Number: NNF18OC0052256 | Start Date*: 2019-12-05 |
Sponsor Name:Lungemedicinsk Forskningsenhed | ||
Full Title: Effects of azithromycin treatment on anti-viral immunity in patients with asthma and COPD. | ||
Medical condition: COPD and asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001120-54 | Sponsor Protocol Number: SQ167015 | Start Date*: 2016-07-25 |
Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust | ||
Full Title: Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage? | ||
Medical condition: Recurrent miscarriage | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003335-29 | Sponsor Protocol Number: SIOPEATRT01 | Start Date*: 2021-04-15 |
Sponsor Name:German Pediatric Oncology Group, GPOH gGmbH | ||
Full Title: An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of hig... | ||
Medical condition: atypical teratoid/rhabdoid tumours (ATRT) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001088-58 | Sponsor Protocol Number: SELLY | Start Date*: 2020-03-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | ||||||||||||||||||
Full Title: SEntinel Lymph node in EarLY ovarian cancer: the SELLY protocol | ||||||||||||||||||
Medical condition: ADVANCED OVARIAN CANCER | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004467-13 | Sponsor Protocol Number: 012255 | Start Date*: 2018-10-02 | |||||||||||
Sponsor Name:Barts Health NHS Trust | |||||||||||||
Full Title: A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancrea... | |||||||||||||
Medical condition: Stage IV pancreatic adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004241-32 | Sponsor Protocol Number: EDOLAS | Start Date*: 2020-02-07 | |||||||||||
Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI | |||||||||||||
Full Title: Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression | |||||||||||||
Medical condition: HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004340-30 | Sponsor Protocol Number: M15-538 | Start Date*: 2020-06-08 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000803-20 | Sponsor Protocol Number: C1071006 | Start Date*: 2022-11-02 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: MAGNETISMM-6: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENA... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) ES (Restarted) CZ (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) HU (Prematurely Ended) FR (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) AT (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003970-41 | Sponsor Protocol Number: CRU3 | Start Date*: 2017-07-06 | |||||||||||
Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA | |||||||||||||
Full Title: A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS | |||||||||||||
Medical condition: Anaplastic Large Cells Lymphoma (ALCL) ALK+ | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002359-39 | Sponsor Protocol Number: 213406 | Start Date*: 2020-09-18 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||||||||||||||||||
Full Title: A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS | ||||||||||||||||||
Medical condition: Recurrent or refractory solid tumour | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005157-75 | Sponsor Protocol Number: EMN12/HO129 | Start Date*: 2015-08-06 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients | |||||||||||||
Medical condition: Primary plasma cell leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Prematurely Ended) NO (Completed) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002428-10 | Sponsor Protocol Number: KTxSGLT2i-22 | Start Date*: 2023-03-06 | |||||||||||
Sponsor Name:Oslo Univeristy Hospital - Rikshospitalet | |||||||||||||
Full Title: CAN DAPAGLIFLOZIN PRESERVE STRUCTURE AND FUNCTION IN TRANSPLANTED KIDNEYS? | |||||||||||||
Medical condition: Kidney transplanted patients. Looking at the effect of SGLT2 inhibitor on graft survival by repeated eGFR measurements, measured GFR, kidney graft biopsies to evaluate inflammation, fibrosis and va... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003105-33 | Sponsor Protocol Number: EMN12/HO129 | Start Date*: 2017-08-02 | |||||||||||
Sponsor Name:HOVON | |||||||||||||
Full Title: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients | |||||||||||||
Medical condition: Primary plasma cell leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002163-17 | Sponsor Protocol Number: 15-138 | Start Date*: 2018-10-25 |
Sponsor Name:RWTH Aachen University represented by the Center for Translational & Clinical Research Aachen (CTC-A) | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. | ||
Medical condition: Friedreich Ataxia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2018-000415-25 | Sponsor Protocol Number: PROSPER | Start Date*: 2018-08-10 | |||||||||||
Sponsor Name:University Hospital Heidelberg | |||||||||||||
Full Title: PANCREATIC RESECTION WITH PERIOPERATIVE OFF-LABEL STUDY OF PROPRANOLOL AND ETODOLAC – A PHASE II RANDOMIZED TRIAL | |||||||||||||
Medical condition: Patients with pancreatic carcinoma treated by pancreatoduodenectomy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
